IL6 and lung disorder: We found that SAHA significantly (p < 0.05) diminishes Pa-LPS induced systemic IL-6 and MPO levels (Fig. 4a and b), suggesting its potential as a therapeutic for controlling chronic inflammation and neutrophil-activation mediated obstructive CF-lung disease.